Open AccessOverview on Juvenile Idiopathic Arthritis: A Review
Author(s) -
Ahlam Shary J. Hazazi,
Badaya Awadh M. Alshehri,
Yara Abdulrahman Alali,
Rahf Mohammed Alqarni,
Ibtisam Shary J Hazazi,
Nujud Abdulqader Albalawi,
Dimah Mohammed A. Abu Murad,
Atheer Mansour E Alatawi,
Nouf Alatawi,
Maisaa Mokhtar M. Yousuf
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i40b32273
Subject(s) - arthritis , medicine , disease , clinical trial , juvenile , intensive care medicine , quality of life (healthcare) , immunology , biology , genetics , nursing
Juvenile idiopathic arthritis (JIA) is a broad term that refers to a clinically heterogeneous group of arthritis that develops before the age of 16 and has no recognized cause. JIA treatment has evolved during the last two decades. Clinical trials research has been directed at more specific therapeutics based on what has been discovered about the biology of disease. Pediatric rheumatologists now have many more medications to offer patients, with the expectation that their disease will be managed, thanks to advances in immune system research and the introduction of biologic drugs in the twenty-first century. Continuing development in these biological agents and discoveries new drugs as long as developing current gene analysis techniques is the best method to treat JIA and provide best quality of life.